492 related articles for article (PubMed ID: 30219952)
1. Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond.
Iqbal J; Abbasi BA; Ahmad R; Mahmood T; Ali B; Khalil AT; Kanwal S; Shah SA; Alam MM; Badshah H; Munir A
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9449-9470. PubMed ID: 30219952
[TBL] [Abstract][Full Text] [Related]
2. Strategies to improve tumor penetration of nanomedicines through nanoparticle design.
Zhang YR; Lin R; Li HJ; He WL; Du JZ; Wang J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1519. PubMed ID: 29659166
[TBL] [Abstract][Full Text] [Related]
3. Improved Targeting of Cancers with Nanotherapeutics.
Foster C; Watson A; Kaplinsky J; Kamaly N
Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
[TBL] [Abstract][Full Text] [Related]
4. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Tumor Penetration of Nanomedicines.
Sun Q; Ojha T; Kiessling F; Lammers T; Shi Y
Biomacromolecules; 2017 May; 18(5):1449-1459. PubMed ID: 28328191
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
Du JZ; Li HJ; Wang J
Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
[TBL] [Abstract][Full Text] [Related]
7. Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery.
Wang X; Zhang H; Chen X; Wu C; Ding K; Sun G; Luo Y; Xiang D
Acta Biomater; 2023 Aug; 166():42-68. PubMed ID: 37257574
[TBL] [Abstract][Full Text] [Related]
8. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
Shi J; Xiao Z; Kamaly N; Farokhzad OC
Acc Chem Res; 2011 Oct; 44(10):1123-34. PubMed ID: 21692448
[TBL] [Abstract][Full Text] [Related]
9. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Durymanov MO; Rosenkranz AA; Sobolev AS
Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
[TBL] [Abstract][Full Text] [Related]
10. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
Sun D; Chen J; Wang Y; Ji H; Peng R; Jin L; Wu W
Theranostics; 2019; 9(23):6885-6900. PubMed ID: 31660075
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicine: An effective tool in cancer therapy.
Aftab S; Shah A; Nadhman A; Kurbanoglu S; Aysıl Ozkan S; Dionysiou DD; Shukla SS; Aminabhavi TM
Int J Pharm; 2018 Apr; 540(1-2):132-149. PubMed ID: 29427746
[TBL] [Abstract][Full Text] [Related]
12. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
13. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
14. Nanoscale drug delivery for targeted chemotherapy.
Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
[TBL] [Abstract][Full Text] [Related]
15. Potential drug delivery nanosystems for improving tumor penetration.
Peng F; Li R; Zhang F; Qin L; Ling G; Zhang P
Eur J Pharm Biopharm; 2020 Jun; 151():220-238. PubMed ID: 32311427
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
17. Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization.
Sun Q; Zhou Z; Qiu N; Shen Y
Adv Mater; 2017 Apr; 29(14):. PubMed ID: 28234430
[TBL] [Abstract][Full Text] [Related]
18. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
Swetha KL; Roy A
Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
[TBL] [Abstract][Full Text] [Related]
20. Promising effects of nanomedicine in cancer drug delivery.
Wakaskar RR
J Drug Target; 2018 Apr; 26(4):319-324. PubMed ID: 28875739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
